Ticker Details
Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
IPO Date:	March 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.75B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 3.16%
Avg Daily Range (30 D):	$0.59 | 2.88%
Avg Daily Range (90 D):	$0.56 | 2.68%

Institutional Daily Volume
Avg Daily Volume:	.66M
Avg Daily Volume (30 D):	1.16M
Avg Daily Volume (90 D):	1.44M

Trade Size
Avg Trade Size (Sh.):	84
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	3,715
Avg Institutional Trade:	$2.33M
Avg Institutional Trade (30 D):	$2.99M
Avg Institutional Trade (90 D):	$2.8M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.14M
Avg Closing Trade (30 D):	$4.65M
Avg Closing Trade (90 D):	$5.52M
Avg Closing Volume:	173.62K

News

May 20, 2026 @ 11:00 AM Syndax Announces Participation in Upcoming Investo... Source: Na

Mar 13, 2026 @ 1:09 PM Cancer Drug Maker With $172 Million Revenue and Mu... Source: Jonathan Ponciano

Jan 7, 2026 @ 12:00 PM Syndax and World Orphan Drug Alliance to Launch a ... Source: Na

Dec 1, 2025 @ 12:00 PM Syndax Announces Participation at the 8th Annual E... Source: Michael A. Metzger

Oct 24, 2025 @ 5:58 PM Syndax Announces FDA Approval of Revuforj® (rev... Source: Syndax Pharmaceuticals

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.52	$-.55	$-.49
Diluted EPS	$-2.52	$-.55	$-.49
Revenue	$252.25M	$72.79M	$64.86M
Gross Profit
Net Income / Loss	$-220.77M	$-49.36M	$-42.67M
Operating Income / Loss	$-194.17M	$-40M	$-34.2M
Cost of Revenue
Net Cash Flow	$227.73M
PE Ratio